Dermatology

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Eli Lilly and presented at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Arcutis Biotherapeutics and presented at the European Academy of Dermatology & Venereology Congress.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

The ESS device, leveraging artificial intelligence, may allow for enhanced decision making among nurse practitioners as well as physician assistants evaluating patients for skin cancer.

A handheld tool improved skin cancer detection in primary care, increasing diagnostic sensitivity to 96.3% compared to 83.9% without the device.

A new case-control study reported a higher prevalence of precocious puberty in children and adolescents with HS compared with controls.

The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.

This conference talk was titled Acute & Chronic Spontaneous Urticaria: Diagnostic and Therapeutic Strategies and presented a challenging case series to attendees.

This segment of her interview featured a conversation about the biggest takeaways and notable case series presented in Culton’s talk at Maui Derm NP+PA Fall.

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.